UK markets closed

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.7440-0.0061 (-0.81%)
At close: 04:33PM GMT

Adverum Biotechnologies, Inc.

800 Saginaw Drive
Redwood City, CA 94063
United States
650 656 9323

Full-time employees188

Key executives

NameTitlePayExercisedYear born
Dr. Laurent FischerPres, CEO & Director921.08kN/A1964
Mr. Kishor Peter Soparkar J.D.Chief Operating Officer622.55kN/A1971
Dr. Brigit Riley Ph.D.Chief Scientific Officer816.08kN/A1978
Ms. Linda M. Rubinstein M.A.CFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1967
Mr. Heikki JouttijarviSr. VP & Head of Technical OperationsN/AN/AN/A
Mr. John W. Rakow J.D.Sr. VP & Gen. CounselN/AN/A1957
Ms. Dena HouseSr. VP of HR, Organizational Devel. & LearningN/AN/AN/A
Ms. Carla FiankanSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Jim Wang Ph.D.Chief Regulatory OfficerN/AN/AN/A
Mr. Michael SteelSr. VP of QualityN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Corporate governance

Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 1 March 2023 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.